TheraRadar
Clinical-Stage Companies / Sumitomo Pharma America

Sumitomo Pharma America

Pre-Approval PRO BETA
131
Total Trials
62
Phase 3
30
Phase 2
6
Recruiting
1336
Score

Pipeline by Phase

Phase 3
62
Phase 2
30
Phase 1
52

Therapeutic Focus

Schizophrenia Perennial Allergic Rhinitis Cancer Advanced Solid Tumors Bipolar Depression

Clinical Trials (131)

NCT05605964 Phase 3 COMPLETED

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Started: 1/28/2023

NCT05227209 Phase 3 TERMINATED

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Started: 3/17/2022

NCT05169710 Phase 3 TERMINATED

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Started: 12/21/2021

NCT02542696 Phase 3 COMPLETED

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Started: 8/31/2015

NCT02993731 Phase 3 COMPLETED

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Started: 12/1/2016

NCT02753127 Phase 3 COMPLETED

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Started: 6/1/2016

NCT02178956 Phase 3 COMPLETED

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Started: 10/1/2014

NCT03149003 Phase 3 COMPLETED

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Started: 12/8/2017

NCT02826161 Phase 3 TERMINATED

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Started: 11/1/2016

NCT03391882 Phase 3 COMPLETED

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Started: 12/19/2018

NCT02684279 Phase 3 COMPLETED

Dasotraline Binge Eating Disorder Extension Study

Started: 2/29/2016

NCT02469090 Phase 3 COMPLETED

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

Started: 6/18/2015

NCT03107026 Phase 3 COMPLETED

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

Started: 3/31/2017

NCT03231800 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Started: 7/31/2017

NCT02734693 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Started: 4/30/2016

NCT02457819 Phase 3 COMPLETED

Dasotraline Pediatric Extension Study

Started: 6/30/2015

NCT01914393 Phase 3 COMPLETED

Pediatric Open-Label Extension Study

Started: 9/30/2013

NCT01566162 Phase 3 COMPLETED

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Started: 4/1/2012

NCT00910247 Phase 3 COMPLETED

Eslicarbazepine Acetate Monotherapy Long Term Study

Started: 8/1/2009

NCT03108729 Phase 3 WITHDRAWN

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

Started: 7/6/2017

NCT02046369 Phase 3 COMPLETED

Lurasidone Pediatric Bipolar Study

Started: 3/1/2014

NCT00857220 Phase 3 COMPLETED

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

Started: 5/1/2009

NCT02276209 Phase 3 COMPLETED

Dasotraline Adult ADHD Study

Started: 12/1/2014

NCT02160262 Phase 3 COMPLETED

Open-label Safety Study in Adults With ADHD

Started: 6/1/2014

NCT01911429 Phase 3 COMPLETED

Pediatric Schizophrenia Efficacy and Safety Study

Started: 8/1/2013

NCT01485640 Phase 3 COMPLETED

Lurasidone Extended Use Study

Started: 6/1/2011

NCT01091662 Phase 3 COMPLETED

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Started: 6/1/2010

NCT01358357 Phase 3 COMPLETED

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

Started: 6/1/2011

NCT01575561 Phase 3 COMPLETED

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

Started: 6/1/2012

NCT01821378 Phase 3 COMPLETED

Lurasidone Low-Dose - High-Dose Study Study

Started: 5/1/2013

NCT01421134 Phase 3 COMPLETED

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

Started: 9/1/2011

NCT00868959 Phase 3 COMPLETED

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Started: 4/1/2009

NCT01435928 Phase 3 COMPLETED

PEARL Schizophrenia Maintenance

Started: 9/1/2011

NCT02150499 Phase 3 TERMINATED

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

Started: 7/1/2014

NCT01423253 Phase 3 COMPLETED

Major Depressive Disorder With Mixed Features - Extension

Started: 9/1/2011

NCT00790023 Phase 3 COMPLETED

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

Started: 11/1/2008

NCT00790192 Phase 3 COMPLETED

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Started: 10/1/2008

NCT00866775 Phase 3 COMPLETED

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Started: 4/1/2009

NCT01911442 Phase 3 COMPLETED

Lurasidone Pediatric Autism Study

Started: 8/1/2013

NCT00641745 Phase 3 COMPLETED

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Started: 3/1/2008

NCT01143090 Phase 3 COMPLETED

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Started: 8/1/2010

NCT00615433 Phase 3 COMPLETED

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Started: 1/1/2008

NCT00789698 Phase 3 COMPLETED

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Started: 12/1/2008

NCT00809757 Phase 3 COMPLETED

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Started: 12/1/2008

NCT01378429 Phase 3 COMPLETED

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

Started: 7/1/2011

NCT01458275 Phase 3 COMPLETED

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Started: 11/1/2011

NCT01451541 Phase 3 COMPLETED

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Started: 10/1/2011

NCT00868452 Phase 3 COMPLETED

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Started: 4/1/2009

NCT00868699 Phase 3 COMPLETED

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Started: 4/1/2009

NCT01284517 Phase 3 COMPLETED

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

Started: 11/1/2010

NCT00909779 Phase 3 COMPLETED

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Started: 6/1/2009

NCT00856973 Phase 3 COMPLETED

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Started: 5/1/2009

NCT01401465 Phase 3 COMPLETED

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

Started: 7/1/2011

NCT01143077 Phase 3 COMPLETED

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Started: 6/1/2010

NCT01423240 Phase 3 WITHDRAWN

Major Depressive Disorder With Mixed Features

Started: 1/1/2012

NCT01287364 Phase 3 COMPLETED

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Started: 2/1/2011

NCT01033825 Phase 3 COMPLETED

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

Started: 1/1/2010

NCT01067105 Phase 3 COMPLETED

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Started: 2/1/2010

NCT01010971 Phase 3 COMPLETED

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Started: 12/1/2009

NCT00953147 Phase 3 COMPLETED

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Started: 8/1/2009

NCT02520011 Phase 2 TERMINATED

Alvocidib Biomarker-driven Phase 2 AML Study

Started: 3/14/2016

NCT02432690 Phase 2 TERMINATED

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

Started: 6/1/2015

NCT01776307 Phase 2 COMPLETED

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Started: 3/1/2012

NCT02232633 Phase 2 COMPLETED

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Started: 2/1/2015

NCT02232646 Phase 2 WITHDRAWN

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Started: 1/1/2017

NCT02232620 Phase 2 TERMINATED

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

Started: 3/13/2017

NCT03969420 Phase 2 TERMINATED

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Started: 1/15/2020

NCT03543410 Phase 2 COMPLETED

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

Started: 6/26/2018

NCT02428088 Phase 2 COMPLETED

Dasotraline Pediatric ADHD Study

Started: 4/1/2015

NCT03292016 Phase 2 COMPLETED

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

Started: 8/22/2017

NCT03187301 Phase 2 COMPLETED

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

Started: 8/3/2017

NCT02228590 Phase 2 COMPLETED

A Study to Examine APL-130277 in Patients With Parkinson's Disease

Started: 8/31/2014

NCT02564588 Phase 2 COMPLETED

Dasotraline Binge Eating Disorder Study

Started: 10/1/2015

NCT00616655 Phase 2 COMPLETED

Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

Started: 1/1/2008

NCT01692782 Phase 2 COMPLETED

Adult Attention Deficit Hyperactivity Disorder

Started: 12/1/2012

NCT00583947 Phase 2 COMPLETED

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

Started: 1/1/2008

NCT04176198 Phase 1 RECRUITING

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Started: 12/16/2019

NCT06891885 Phase 1 RECRUITING

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Started: 4/16/2026

NCT07444268 Phase 1 RECRUITING

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Started: 3/26/2026

NCT04988555 Phase 1 RECRUITING

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Started: 2/28/2022

NCT06753331 Phase 1 RECRUITING

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Started: 12/18/2024

NCT06526819 Phase 1 RECRUITING

SMP-3124LP in Adults With Advanced Solid Tumors

Started: 8/14/2024

NCT07492355 Phase 1 COMPLETED

TP-3654 Food Effect Study

Started: 3/4/2024

NCT04666129 Phase 1 COMPLETED

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Started: 2/18/2021

NCT04328740 Phase 1 COMPLETED

Phase 1 Study of Oral TP-1454

Started: 7/8/2020

NCT03604783 Phase 1 TERMINATED

Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Started: 12/26/2018

NCT06389955 Phase 1 COMPLETED

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

Started: 5/22/2023

NCT03416335 Phase 1 TERMINATED

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Started: 6/1/2018

NCT03311334 Phase 1 TERMINATED

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Started: 12/14/2017

NCT02231723 Phase 1 COMPLETED

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Started: 8/1/2014

NCT01325441 Phase 1 COMPLETED

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Started: 4/1/2011

NCT02279719 Phase 1 COMPLETED

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Started: 12/1/2014

NCT03298984 Phase 1 COMPLETED

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Started: 9/25/2017

NCT02024607 Phase 1 COMPLETED

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Started: 1/1/2014

NCT02315534 Phase 1 COMPLETED

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

Started: 3/1/2015

NCT02467361 Phase 1 COMPLETED

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

Started: 8/1/2015

NCT01781455 Phase 1 COMPLETED

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

Started: 2/1/2012

NCT03411122 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Started: 6/30/2017

NCT01775423 Phase 1 COMPLETED

A Study of BBI608 in Adult Patients With Advanced Malignancies

Started: 3/1/2009

NCT02352558 Phase 1 COMPLETED

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Started: 5/1/2015

NCT03429218 Phase 1 COMPLETED

First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

Started: 7/10/2018

NCT02729298 Phase 1 COMPLETED

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Started: 12/14/2016

NCT02498665 Phase 1 COMPLETED

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Started: 11/1/2015

NCT03715504 Phase 1 COMPLETED

Study of TP-3654 in Patients With Advanced Solid Tumors

Started: 4/16/2019

NCT02483247 Phase 1 COMPLETED

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Started: 9/1/2015

NCT03416816 Phase 1 TERMINATED

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Started: 5/15/2018

NCT03572634 Phase 1 TERMINATED

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Started: 6/10/2019

NCT04623996 Phase 1 TERMINATED

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Started: 12/28/2020

NCT03593915 Phase 1 TERMINATED

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Started: 8/29/2018

NCT02432326 Phase 1 COMPLETED

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Started: 4/1/2015

NCT03525405 Phase 1 COMPLETED

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Started: 5/18/2018

NCT04299880 Phase 1 COMPLETED

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Started: 2/24/2020

NCT03627195 Phase 1 COMPLETED

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

Started: 6/7/2018

NCT01621542 Phase 1 COMPLETED

Clinical Study of WT2725 in Patients With Advanced Malignancies

Started: 7/31/2012

NCT02795637 Phase 1 COMPLETED

Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction

Started: 5/1/2016

NCT01620060 Phase 1 COMPLETED

Lurasidone Pediatric Pharmacokinetics Study

Started: 6/1/2012

NCT02195167 Phase 1 COMPLETED

Dasotraline SEP360-105 Pediatric PK/PD Study

Started: 7/1/2014

NCT01774747 Phase 1 TERMINATED

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

Started: 12/1/2012

NCT01082146 Phase 1 COMPLETED

RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

Started: 8/1/2008

NCT01531972 Phase 1 COMPLETED

A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

Started: 2/1/2012

NCT01042106 Phase 1 COMPLETED

Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults

Started: 11/1/2009

NCT01371786 Phase 1 COMPLETED

A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler

Started: 6/1/2011

NCT01074632 Phase 1 COMPLETED

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Started: 5/1/2009

NCT01082263 Phase 1 COMPLETED

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

Started: 10/1/2008

NCT01082250 Phase 1 COMPLETED

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

Started: 7/1/2008

NCT01074073 Phase 1 COMPLETED

Lithium Drug-Drug Interaction Study With Lurasidone HCl

Started: 8/1/2008

NCT01082289 Phase 1 COMPLETED

Digoxin Drug-Drug Interaction With Lurasidone HCl

Started: 9/1/2008

NCT01082276 Phase 1 COMPLETED

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

Started: 8/1/2008

NCT03116828 Phase 4 COMPLETED

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Started: 7/7/2017

NCT02275481 Phase 4 TERMINATED

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Started: 11/1/2014

NCT01654536 Phase 4 COMPLETED

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Started: 9/1/2012

Drug Candidates

Nusivertib DSP-3077 Retinal Sheet Cohort 1 DSP-3077 Retinal Sheet Cohort 2 DSP-3077 Retinal Sheet Cohort 3 DSP-5336 [14C]-DSP-5336 TP-3654 Enzomenib azoles Intensive chemotherapy with 7 + 3
Activity Status: Active
Last Trial Started: 4/16/2026
Last Trial Ended: 4/25/2025
Trials (12 months): 2
Completed Trials: 105
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.